Prostate Cancer Diagnosis
Tracking # 20-848196
Course overview
The US Centers for Disease Control has listed prostate cancer as causing the second highest cancer deaths among males in the US and the leading new type of cancer diagnosed among males. This activity includes updated information on PSA testing, the pros and cons of PSA testing, other methods currently used for diagnosing prostate cancer, and new methods under development.
Subject areas
This course counts toward the state boards and subject areas below.
Bahamas Medical Council
Medical Practitioner
1.25h
Urology
Specialty Medical Practitioner
1.25h
Urology
Florida Board of Medicine
Medical Doctor
1.25h
General (AMA Category I)
Georgia Composite Medical Board - Physicians & Telemedicine
Institutional Physician
1.25h
General CME
Physician
1.25h
General CME
Telemedicine
1.25h
General CME
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
1.25h
Category I CME
Michigan Board of Medicine
Medical Doctor
1.25h
Category 1 Hours
Medical Doctor Compact License
1.25h
Category 1 Hours
Mississippi State Board of Medical Licensure
Doctor of Osteopathy
1.25h
AMA Category I
Medical Doctor
1.25h
AMA Category I
Physician Assistant
1.25h
AMA Category I
New Hampshire Board of Medicine
Physician
1.25h
Category 1 Hours
New Mexico Medical Board
Medical Doctor
1.25h
General CME - AMA/AOA Category 1
Oklahoma Board of Medical Licensure and Supervision - Medical Doctors
Medical Doctor
1.25h
Category I CME
South Carolina Board of Medical Examiners
Doctor of Osteopathy
1.25h
Urology
Medical Doctor
1.25h
Urology
State Medical Board of Ohio
Doctor of Medicine
1.25h
AMA Category I
Doctor of Osteopathic Medicine
1.25h
AMA Category I
Tennessee Board of Medical Examiners
Medical Doctor
1.25h
AMA Category I CME
Tennessee Board of Osteopathic Examination
Osteopathic Physician
1.25h
AMA Category I CME
Disclosure statements
The authors, editors, reviewers and planning committee members for this activity have no relevant financial relationships with an ACCME-defined ineligible company to disclose.